Thermo Fisher Scientific agreed to acquire Clario for $8.9 billion in cash (plus an additional earnout), folding the clinical‑trial data and patient‑centric platform into its portfolio. The purchase expands Thermo Fisher’s footprint in trial data solutions, eClinical platforms and decentralized trial capabilities. The deal reflects continued consolidation as life‑science service providers scale up offerings across data management, trial operations and analytics. Thermo Fisher expects the acquisition to accelerate its strategy to provide end‑to‑end solutions across R&D and clinical operations. Large strategic buys for data‑solution firms signal investor and corporate confidence in the long‑term value of digital trial infrastructure and real‑world data capabilities.